Annals of OncologyPub Date : 2025-07-05DOI: 10.1016/j.annonc.2025.06.018
F Castet, T V Tian, T Macarulla
{"title":"Comparative genomic landscape of acquired resistance in pancreatic cancer treated with pan-RAS or KRAS<sup>G12C</sup> inhibitors.","authors":"F Castet, T V Tian, T Macarulla","doi":"10.1016/j.annonc.2025.06.018","DOIUrl":"10.1016/j.annonc.2025.06.018","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144582892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Annals of OncologyPub Date : 2025-07-05DOI: 10.1016/j.annonc.2025.06.015
A Mamann, Y Pradat, F C Bidard, S Delaloge, L Cabel, I Faull, S Marques, T Bachelot, F Dalenc, T DE LA Motte Rouge, B Pistilli, J Samaniego, J S Frenel, C Levy, J M Ferrero, R Sabatier, S Ladoire, C Chakiba, A C Hardy, J Lemonnier, Y Mahi, F Andre, P H Cournede, S Michiels, E Bernard
{"title":"Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER+/HER2- breast cancer.","authors":"A Mamann, Y Pradat, F C Bidard, S Delaloge, L Cabel, I Faull, S Marques, T Bachelot, F Dalenc, T DE LA Motte Rouge, B Pistilli, J Samaniego, J S Frenel, C Levy, J M Ferrero, R Sabatier, S Ladoire, C Chakiba, A C Hardy, J Lemonnier, Y Mahi, F Andre, P H Cournede, S Michiels, E Bernard","doi":"10.1016/j.annonc.2025.06.015","DOIUrl":"https://doi.org/10.1016/j.annonc.2025.06.015","url":null,"abstract":"<p><strong>Background: </strong>Patients with advanced estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer commonly develop resistance to treatment with hormone therapy and cyclin-dependent kinases 4/6 (CDK4/6) inhibitors. Responders cannot be distinguished from non-responders after the first cycle of treatment under current practice. We assessed circulating tumor DNA (ctDNA) measures at early time-points as prognostic markers.</p><p><strong>Patients and methods: </strong>Paired plasma samples were collected at baseline and early on-treatment (median 28 days) from 369 patients with advanced ER+/HER2- breast cancer treated in the PADA-1 trial with hormone therapy and a CDK4/6 inhibitor. Cell-free DNA was profiled with a 497-gene panel (Guardant360 LDT).</p><p><strong>Results: </strong>Baseline ctDNA levels including the mean variant allele frequency (VAF) (progression-free survival [PFS] HR = 1.07 [1.05, 1.09] P<0.001, overall survival [OS] HR = 1.08 [1.05, 1.11] P<0.001) and the number of driver somatic mutations (PFS HR = 1.13 [1.07, 1.19], P<0.001 and OS HR = 1.16 [1.07, 1.24], P<0.001) were prognostic. Early on-treatment ctDNA dynamics were also associated with outcomes, including the number of driver somatic mutations with VAF>0.5% at both timepoints (PFS HR = 1.39 [1.27,1.53] P<0.001 and OS HR = 1.51 [1.35,1.68] P<0.001) and the number of driver somatic mutations with a VAF increase (PFS HR = 1.31 [1.19,1.44] P<0.001 and OS HR = 1.10 [1.02,1.18] P=0.02). A ctDNA-based risk model incorporating baseline and dynamic ctDNA features was independently prognostic from RECIST in multivariable models (Test set: OS HR = 4.10 [1.93,8.72], P<0.001, PFS HR = 1.86 [1.16,2.97], P=0.009). The integration of ctDNA features into a clinical model improved survival discrimination for PFS (C-index 64.7% [s.d. 2.5] for a ctDNA & clinical model vs. 59.3% [s.d. 2.2] for a clinical only model, p=0.027) and for OS (C-index 70.0% [s.d 3.4] vs. 60.3% [s.d. 4.2], p=0.035).</p><p><strong>Conclusions: </strong>Early on-treatment evolution of ctDNA is prognostic for both PFS and OS in advanced ER+/HER2- breast cancer. A ctDNA-based risk model improves upon traditional RECIST and clinical parameters, advocating for ctDNA as a prognostic biomarker in clinical practice.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144582893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Annals of OncologyPub Date : 2025-07-01DOI: 10.1016/j.annonc.2025.05.035
N. Martinez Lago , M. Sanchez Ares , A. Carral Maseda , M. Perez Martelo , M. Covela , A. Fernandez Montes , J. de la Camara Gomez , P. González Villarroel , M. Reboredo López , M.E. Padin Iruegas , I. Abdulkader Nallib
{"title":"23P Prognostic impact of secondary actionable alterations in dMMR/MSI-H digestive tumors","authors":"N. Martinez Lago , M. Sanchez Ares , A. Carral Maseda , M. Perez Martelo , M. Covela , A. Fernandez Montes , J. de la Camara Gomez , P. González Villarroel , M. Reboredo López , M.E. Padin Iruegas , I. Abdulkader Nallib","doi":"10.1016/j.annonc.2025.05.035","DOIUrl":"10.1016/j.annonc.2025.05.035","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S15"},"PeriodicalIF":56.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Annals of OncologyPub Date : 2025-07-01DOI: 10.1016/j.annonc.2025.05.072
E. Osterlund , S. Aho , A. Uutela , K.I. Lehtomaki , L. Nunes , P. Pfeiffer , H. Sorbye , T.T. Muhonen , E. Heerva , A. Algars , R. Ristamaki , H.P. Stedt , A. Lamminmäki , R. Kallio , T. Salminen , P. Halonen , A. Nordin , H. Isoniemi , B. Glimelius , P.J. Osterlund
{"title":"60P No liver metastases vs liver metastases in metastatic colorectal cancer (mCRC)","authors":"E. Osterlund , S. Aho , A. Uutela , K.I. Lehtomaki , L. Nunes , P. Pfeiffer , H. Sorbye , T.T. Muhonen , E. Heerva , A. Algars , R. Ristamaki , H.P. Stedt , A. Lamminmäki , R. Kallio , T. Salminen , P. Halonen , A. Nordin , H. Isoniemi , B. Glimelius , P.J. Osterlund","doi":"10.1016/j.annonc.2025.05.072","DOIUrl":"10.1016/j.annonc.2025.05.072","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S33"},"PeriodicalIF":56.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Annals of OncologyPub Date : 2025-07-01DOI: 10.1016/j.annonc.2025.05.084
A. Pretta , V. Nasca , F. Marmorino , R. Intini , P. Ziranu , G. Randon , M. Carullo , K. Cerma , C. Donisi , C. Damonte , A. Taravella , C. Gaiani , S. Mariani , I. Montroni , P. Ciracì , A. De Rosa , F. Bergamo , C. Cremolini , F. Pietrantonio , M. Scartozzi
{"title":"72P Early-onset colorectal cancer patients exhibits a distinct molecular fingerprint: Insights from a study of 1209 patients using NGS","authors":"A. Pretta , V. Nasca , F. Marmorino , R. Intini , P. Ziranu , G. Randon , M. Carullo , K. Cerma , C. Donisi , C. Damonte , A. Taravella , C. Gaiani , S. Mariani , I. Montroni , P. Ciracì , A. De Rosa , F. Bergamo , C. Cremolini , F. Pietrantonio , M. Scartozzi","doi":"10.1016/j.annonc.2025.05.084","DOIUrl":"10.1016/j.annonc.2025.05.084","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S39"},"PeriodicalIF":56.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144634373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Annals of OncologyPub Date : 2025-07-01DOI: 10.1016/j.annonc.2025.05.101
J.P.Y-C. Shen , M.C. Cobanoglu , Y. Jiang , S. Dashner , V. Aushev , H. Mickalide , F. Mendez , J. Rodriguez-Medina , J.N. Burton , T. Constantin , S.L. Bristow , A. Jurdi , A. Aleshin , T. Kawli , J.G. Reiter
{"title":"89P Development of methylation-based biomarkers to predict metastases, treatment effect, and microsatellite status in colorectal cancer","authors":"J.P.Y-C. Shen , M.C. Cobanoglu , Y. Jiang , S. Dashner , V. Aushev , H. Mickalide , F. Mendez , J. Rodriguez-Medina , J.N. Burton , T. Constantin , S.L. Bristow , A. Jurdi , A. Aleshin , T. Kawli , J.G. Reiter","doi":"10.1016/j.annonc.2025.05.101","DOIUrl":"10.1016/j.annonc.2025.05.101","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S44"},"PeriodicalIF":56.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}